rizatriptan has been researched along with Abnormalities, Drug-Induced in 1 studies
rizatriptan: structure given in first source; RN given refers to benzoate
Abnormalities, Drug-Induced: Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| " evaluates outcomes of the use of rizatriptan during pregnancy through a Pregnancy Registry in the United States (US) and spontaneous reports for pregnancies reported from sources outside the US." | 7.73 | Exposure to rizatriptan during pregnancy: post-marketing experience up to 30 June 2004. ( Fiore, M; Goldberg, MR; Santanello, N; Shields, KE, 2005) |
| " evaluates outcomes of the use of rizatriptan during pregnancy through a Pregnancy Registry in the United States (US) and spontaneous reports for pregnancies reported from sources outside the US." | 3.73 | Exposure to rizatriptan during pregnancy: post-marketing experience up to 30 June 2004. ( Fiore, M; Goldberg, MR; Santanello, N; Shields, KE, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fiore, M | 1 |
| Shields, KE | 1 |
| Santanello, N | 1 |
| Goldberg, MR | 1 |
1 other study available for rizatriptan and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Exposure to rizatriptan during pregnancy: post-marketing experience up to 30 June 2004.
Topics: Abnormalities, Drug-Induced; Female; Humans; Pregnancy; Pregnancy Outcome; Registries; Serotonin Rec | 2005 |